Table 3.
Select clinical trials of Mcl-1-specific inhibitors
| Mcl-1 inhibitor | Clinical trial number | Phase | Intervention | Disease | Status |
|---|---|---|---|---|---|
| MIK665 (S64315) | NCT02992483 | I | MIK665 (S64315) | MM, DLBCL, and lymphoma | Completed |
| MIK665 (S64315) | NCT04702425 | I | MIK665 in combination with Bcl-2 inhibitor VOB560 | NHL, AML, and MM | Ongoing |
| MIK665 (S64315) | NCT04629443 | I/II | S64315 plus azacitidine | AML | Ongoing |
| MIK665 (S64315) | NCT02979366 | I | S64315 | AML and MDS | Completed |
| S64315 | NCT03672695 | I | S64315 plus venetoclax | AML | Ongoing |
| Gossypol (AT-101) | NCT00390403 | I | AT-101 plus temozolomide with or without radiation therapy | Glioblastoma multiforme | Completed |
| AMG176 | NCT02675452 | I | AMG176, azacitidine, itraconazole | Relapsed or refractory MM and AML | Ongoing |
| AMG397 | NCT03465540 | I | AMG397, azacitidine, dexamethasone | MM, AML, NHL, and MDS | Terminated |
DLBCL: diffuse large B-cell lymphoma; MDS: myelodysplastic syndrome. Source: clinicaltrials.gov